The earnings call presented a strong focus on the successful launch and market acceptance of the AYON Body Contouring System, with substantial revenue growth in the Surgical Aesthetics segment. Despite declines in OEM revenue and international sales, the company's strategic focus on AYON and improved financial health contribute to a positive outlook.
Company Guidance
In the recent earnings call, Apyx Medical provided updated guidance for the full year 2025, reflecting optimism following the successful launch of the AYON Body Contouring System. The company increased its revenue target to a range of $50.5 million to $52.5 million, up from the prior range of $50 million to $52 million, driven largely by the strong performance of the Surgical Aesthetics segment. This segment alone is expected to generate between $43 million and $45 million in revenue, reflecting the robust sales of AYON and an increased volume of single-use handpieces. Despite a slight decline in OEM revenue, the company reported a 12% year-over-year increase in total revenue for Q3 2025, reaching $12.9 million. Gross margins improved to 64.4% from 60.5%, and operating expenses decreased significantly, leading to a 77% reduction in the loss from operations. The company anticipates gross margins of around 61% for the full year and expects total operating expenses to remain below $40 million.
AYON Body Contouring System Launch
The successful launch of the AYON Body Contouring System has driven significant growth, with U.S. sales increasing over 30% for the quarter. The product launch has been met with strong market feedback and initial sales have exceeded expectations.
Revenue Growth
Total revenue for the third quarter increased by 12% to $12.9 million, compared to $11.5 million in the prior year period. The Surgical Aesthetics segment saw a revenue increase of 19%, reaching $11.1 million.
Improved Financial Health
Operating expenses decreased to $9.1 million from $10.6 million, contributing to a 77% decrease in loss from operations. The company also achieved a 96% decrease in adjusted EBITDA loss.
Strategic Rebranding
The company's Advanced Energy segment has been rebranded as Surgical Aesthetics to better align with the company's mission and market focus.
Apyx Medical (APYX) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APYX Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$3.14
$3.35
+6.69%
Aug 07, 2025
$1.96
$2.18
+11.22%
May 08, 2025
$1.25
$1.18
-5.60%
Mar 13, 2025
$1.07
$1.04
-2.80%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Apyx Medical (APYX) report earnings?
Apyx Medical (APYX) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).
What is Apyx Medical (APYX) earnings time?
Apyx Medical (APYX) earnings time is at Mar 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.